Clinical Trials
19 trialsNCT06104449 2026-04-27
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06136598 2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02776436 2026-02-17
REDEX
Leiden University Medical Center
Phase 1 Completed
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00060398 2023-06-15
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00288080 2022-06-21
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01036594 2020-06-29
Keto/Dex
University of California, San Francisco
Phase 2 Completed
NCT01867710 2019-07-05
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
Janssen Pharmaceutica N.V., Belgium
Phase 2 Completed
NCT02047253 2018-12-19
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
University of Alabama at Birmingham
Phase 2 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT00427999 2016-11-21
INV342
Novartis
Phase 2 Completed
NCT01188187 2016-10-14
SYNERGY
Achieve Life Sciences
Phase 3 Completed
NCT00010231 2015-03-30
Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
University of Pittsburgh
Phase 1 Completed
NCT00473746 2014-04-29
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT00473512 2014-03-27
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
Cougar Biotechnology, Inc.
Phase 1/2 Completed
NCT01250717 2014-02-04
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00006002 2013-09-05
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
University of Chicago
Phase 2 Completed
NCT00316927 2013-06-26
Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00054522 2011-03-08
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy
Roswell Park Cancer Institute
Phase 2 Completed